- Home
- NPWR vs PCRX Comparison
NPWR vs PCRX Comparison
Compare NPWR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- PCRX
- Stock Information
- Founded
- NPWR 2010
- PCRX 2006
- Country
- NPWR United States
- PCRX United States
- Employees
- NPWR N/A
- PCRX N/A
- Industry
- NPWR Industrial Machinery/Components
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- PCRX Health Care
- Exchange
- NPWR Nasdaq
- PCRX Nasdaq
- Market Cap
- NPWR 726.1M
- PCRX 1.2B
- IPO Year
- NPWR N/A
- PCRX 2011
- Fundamental
- Price
- NPWR $8.43
- PCRX $26.59
- Analyst Decision
- NPWR Hold
- PCRX Buy
- Analyst Count
- NPWR 2
- PCRX 10
- Target Price
- NPWR $9.50
- PCRX $29.30
- AVG Volume (30 Days)
- NPWR 580.5K
- PCRX 892.8K
- Earning Date
- NPWR 03-10-2025
- PCRX 02-27-2025
- Dividend Yield
- NPWR N/A
- PCRX N/A
- EPS Growth
- NPWR N/A
- PCRX N/A
- EPS
- NPWR 0.11
- PCRX N/A
- Revenue
- NPWR $250,000.00
- PCRX $694,957,000.00
- Revenue This Year
- NPWR N/A
- PCRX $5.14
- Revenue Next Year
- NPWR $6,300.00
- PCRX $2.44
- P/E Ratio
- NPWR $81.29
- PCRX N/A
- Revenue Growth
- NPWR 38.12
- PCRX 4.40
- 52 Week Low
- NPWR $6.57
- PCRX $11.16
- 52 Week High
- NPWR $14.28
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- NPWR 38.49
- PCRX 77.75
- Support Level
- NPWR $7.53
- PCRX $25.06
- Resistance Level
- NPWR $8.98
- PCRX $27.10
- Average True Range (ATR)
- NPWR 0.59
- PCRX 1.45
- MACD
- NPWR -0.08
- PCRX 0.28
- Stochastic Oscillator
- NPWR 34.32
- PCRX 86.23
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.